Control Bionics Ltd
ASX:CBL

Watchlist Manager
Control Bionics Ltd Logo
Control Bionics Ltd
ASX:CBL
Watchlist
Price: 0.063 AUD 3.28% Market Closed
Market Cap: AU$26m

Control Bionics Ltd
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Control Bionics Ltd
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Control Bionics Ltd
ASX:CBL
Non-Reccuring Items
-AU$10.1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Somnomed Ltd
ASX:SOM
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cochlear Ltd
ASX:COH
Non-Reccuring Items
-AU$33.8m
CAGR 3-Years
-61%
CAGR 5-Years
41%
CAGR 10-Years
-10%
Optiscan Imaging Ltd
ASX:OIL
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Austco Healthcare Ltd
ASX:AHC
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Control Bionics Ltd
Glance View

Market Cap
26m AUD
Industry
Health Care

Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-07. The firm is principally engaged in development, commercialization and sale of assistive communications technology systems namely NeuroNode within the disability sector. The Group’s core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment and external control of other devices. Its NeuroNode Trilogy system combines its NeuroNode with eye-gaze technology to create a communication system. Its NeuroNode3 combines the NeuroNode wearable device with operating systems and is suitable for users with severe impairment. Its geographical locations consist of Australia, which is engaged in sales of Trilogy units and components in Australia, and North America, which is engaged in manufacturing and sales of Trilogy units and components in North America.

CBL Intrinsic Value
0.052 AUD
Overvaluation 18%
Intrinsic Value
Price AU$0.063

See Also

What is Control Bionics Ltd's Non-Reccuring Items?
Non-Reccuring Items
-10.1k AUD

Based on the financial report for Jun 30, 2025, Control Bionics Ltd's Non-Reccuring Items amounts to -10.1k AUD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett